Amphastar Pharmaceuticals (AMPH)
(Delayed Data from NSDQ)
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.57 USD
+1.28 (2.77%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $47.56 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum B VGM
Zacks News
The Zacks Analyst Blog Highlights Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations
by Zacks Equity Research
Abercrombie & Fitch, InterDigital, Shake Shack, Amphastar and PGT Innovations are included in this Analyst Blog.
5 Must-Buy High-Flying Mid-Caps to Enhance Your Portfolio
by Nalak Das
We have narrowed our search to five mid-cap stocks with more than 50% returns year to date. These are: PGTI, SHAK, IDCC, ANF, AMPH.
BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?
by Zacks Equity Research
BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $55.87, moving +1.07% from the previous trading session.
Here's Why Investors Should Add Encompass Health (EHC) to Portfolio
by Zacks Equity Research
Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.
Amphastar (AMPH) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Align Technology (ALGN) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.
Zacks.com featured highlights include PDD Holdings, Amphastar Pharmaceuticals and Suzano
by Zacks Equity Research
PDD Holdings, Amphastar Pharmaceuticals and Suzano are part of the Zacks Screen of the Week article.
3 Profitable Stocks Worth Investing in Using Net Income Ratio
by Tirthankar Chakraborty
PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.
Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know
by Zacks Equity Research
Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now
by Zacks Equity Research
HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.
3 Reasons Growth Investors Will Love Amphastar (AMPH)
by Zacks Equity Research
Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
4 Top-Ranked Profitable Stocks to Buy Using Net Income Ratio
by Tirthankar Chakraborty
PDD Holdings Inc. (PDD), Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH) and Axon Enterprise (AXON) have been selected as the top picks with a high net income ratio.
Centene (CNC) Divests Apixio to Boost Its Core Business
by Zacks Equity Research
Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.
Centene (CNC) to Provide Managed Care for SoonerSelect Program
by Zacks Equity Research
Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.
Here is Why Growth Investors Should Buy Amphastar (AMPH) Now
by Zacks Equity Research
Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.
Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Zacks.com featured highlights include Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings
by Zacks Equity Research
Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings are part of the Zacks Screen of the Week article.
4 Solid Profitable Stocks to Invest in Using Net Income Ratio
by Tirthankar Chakraborty
Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH), Turkcell Iletisim Hizmetleri (TKC) and Copa Holdings (CPA) have been selected as the top picks with a high net income ratio.
Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?
by Zacks Equity Research
Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.
Factors That Make Ensign Group (ENSG) a Lucrative Bet Now
by Zacks Equity Research
Ensign Group (ENSG) is well-poised for growth on increasing service revenues, an expanding healthcare portfolio and a strong capital position.
Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now
by Zacks Equity Research
Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.
Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical
by Zacks Equity Research
Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.
Looking for a Growth Stock? 3 Reasons Why Amphastar (AMPH) is a Solid Choice
by Zacks Equity Research
Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.